Updates on eosinophilic disorders.
Tzankov A, Reichard KK, Hasserjian RP, Arber DA, Orazi A, Wang SA.
Virchows Arch. 2023 Jan;482(1):85-97. doi: 10.1007/s00428-022-03402-8. Epub 2022 Sep 7.
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J.
Am J Hematol. 2024 May;99(5):946-968. doi: 10.1002/ajh.27287. Epub 2024 Mar 29.
Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
Requena G, van den Bosch J, Akuthota P, Kovalszki A, Steinfeld J, Kwon N, Van Dyke MK.
J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22.
[Chronic neutrophilic leukemia/chronic eosinophilic leukemia].
Kawashima I, Kirito K.
Rinsho Ketsueki. 2023;64(10):1326-1334. doi: 10.11406/rinketsu.64.1326.
Gene therapy in a murine model of chronic eosinophilic leukemia-not otherwise specified (CEL-NOS).
Pagovich OE, Stiles KM, Camilleri AE, Russo AR, Nag S, Crystal RG.
Leukemia. 2022 Feb;36(2):525-531. doi: 10.1038/s41375-021-01400-4. Epub 2021 Sep 20.
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.
Su RJ, Jonas BA, Welborn J, Gregg JP, Chen M.
Hum Pathol (N Y). 2016 Sep;5:6-9. doi: 10.1016/j.ehpc.2015.10.001.
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
Morsia E, Reichard K, Pardanani A, Tefferi A, Gangat N.
Am J Hematol. 2020 Jul;95(7):E172-E174. doi: 10.1002/ajh.25811. Epub 2020 Apr 17.
A novel activating JAK1 mutation in chronic eosinophilic leukemia.
Shomali W, Damnernsawad A, Theparee T, Sampson D, Morrow Q, Yang F, Fernandez-Pol S, Press R, Zehnder J, Tyner JW, Gotlib J.
Blood Adv. 2021 Sep 28;5(18):3581-3586. doi: 10.1182/bloodadvances.2021004237.
Charcot-Leyden crystals in chronic eosinophilic leukemia.
Sandberg Y, Weerkamp F.
Blood. 2021 Apr 8;137(14):1985. doi: 10.1182/blood.2020010648.
Chronic eosinophilic leukemia with a novel JAK1 mutation responds well to the JAK1/2 inhibitor ruxolitinib.
Wei Q, Xu J.
Blood. 2024 Jul 11;144(2):238. doi: 10.1182/blood.2024024626.
